Pradaxa Bleeding Events Prompt FDA To Revise Generic Bioequivalence Criteria
This article was originally published in The Pink Sheet Daily
Executive Summary
Revamped ANDA instructions – among new and revised draft guidance for 58 products announced by FDA – 'account for the fact that dabigatran exhibits large within-subject variability with respect to blood levels.'